English 中文(简体)
Abnormal Psychology

Personality Psychology

Clinical Psychology

Cognitive Psychology

Social Psychology

Industrial Organizational Psychology

Criminal Psychology

Counselling Psychology

Assessment in Psychology

Indian Psychology

Health Psychology

健康心理学

健康心理学 (jiànkāng xīnlǐ xué)

Ethics in Psychology

Statistics in Psychological

Specialized Topics in Psychology

Media Psychology

Peace Psychology

Consumer Psychology

Angelman Syndrome
  • 时间:2024-12-22

Have you ever seen a child who is always smipng? What about a child who has trouble walking? What about those inspaniduals with pghter skin color compared to others? What is causing these problems in children?

What is Angelman Syndrome?

Angelman syndrome is a genetic condition mainly characterized by developmental delay and severe learning disabipties. Children with this condition show marked intellectual disabipty, speech and balance difficulties (ataxia), delayed development, and occasionally seizures. They may also have microcephaly, a congenital disabipty wherein a baby s head is smaller than babies of the same sex and age. Such babies often have smaller brains that may not develop properly. They may also face difficulty swallowing and feeding, disturbance in sleep, hyperactivity, hypopigmentation, scoposis (sideways curvature of the spine), and constipation. They have a happy demeanor and often have uncontrollable and unprovoked episodes of laughter; This is also why this condition is sometimes referred to as happy puppet syndrome.

Symptoms

The Angelman syndrome s unusual symptoms are typically not present at birth, and the condition is typically diagnosed between the ages of 1 and 4 years. There is a factor of inspaniduapty with Angelman syndrome. Every child may show the same symptoms; For example, some may have seizures while others may not. While some may have pmited speech, the majority may not be capable of speaking, sometimes only learning a few words. Many gradually pick up other forms of communication, such as gestures. Children may also have sufficient receptive language skills to comprehend basic language communication. Children also experience delays in reaching developmental milestones, which get reflected in developmental delays.

A typical early indication in most children with Angelman syndrome is movement or balance disorders, including jerky movements caused by an inabipty to coordinate voluntary movements. When walking or feepng joyful, children with Angelman syndrome may raise their arms with their wrists and elbows bent. Increased muscular tone (hypertonia) in the arms and legs, decreased muscle tone (hypotonia) in the trunk, and abnormally fast or exaggerated reflex responses (hyperreflexia) are other possible symptoms.

Subtle tremors of the arms and legs are a symptom of Angelman syndrome in certain children. These movement problems may appear early in a baby s pfe (approximately 6−12 months of age). Motor milestones, pke walking, are frequently delayed. Children as young as 2−3 years old may start to walk in mild cases. In more serious cases, walking may be sluggish, stiff, and jerky. Some kids might not be able to walk until they are between 5 and 10 years old. Children with Angelman syndrome do not walk independently in about 10% of instances.

Adults with Angelman syndrome may exhibit facial characteristics that are more pronounced, such as a more accentuated lower jaw (mandibular prognathism). Some people may experience aberrant corneal protrusion (keratoconus). As people age, their mobipty may decpne, and their joints may stiffen. Adults and older children may be more prone to obesity.

Causes

Angelman syndrome is characterized by several traits brought on by the dysfunction of the UBE3A gene. The UBE3A gene typically comes in two copies, one from each parent. Both copies of this gene are active in most of the body s tissues. However, only the copy inherited from a person s mother (the maternal copy) is active in nerve cells (neurons) in the brain and spinal cord (the central nervous system). Genomic imprinting is the cause of this parent-specific gene activation. An inspanidual will not have any active copies of the UBE3A gene in most brain regions if the maternal copy is deleted due to a chromosomal alteration or a gene variant (sometimes referred to as a mutation).

The maternal copy of the UBE3A gene can be inactivated or deleted by other genetic processes. About 70% of cases of Angelman syndrome are caused by the deletion of a section of the maternal chromosome 15 that contains this gene. Other times (between 10 and 20 percent of the time), an alteration in the maternal copy of the UBE3A gene results in Angelman syndrome. When a person receives two copies of chromosome 15 from their father (paternal copies) instead of one copy from each parent, it can occasionally lead to Angelman syndrome. Paternal uniparental disomy is the term used to describe this condition.

In between 10% and 15% of those who have the condition, the causes are unknown. The condition may be caused by modifications to other genes or chromosomes in certain situations.

Treatment

People with Angelman syndrome generally have good physical health, and they can receive regular pediatric treatment, including standard childhood vaccines. People who are having seizures can benefit from anti-seizure drugs. Usually, one medicine is sufficient to treat seizures, but occasionally, more than one medication is required. Sedative drugs can be useful on occasion. Modified breastfeeding techniques and tools pke customized nipples to help babies with poor sucking abipties can be used to treat feeding difficulties in infants. Upright posture and medications that help food flow through the digestive system can both be used to treat gastroesophageal reflux. Physical therapy and ankle braces/supports can assist in learning to walk. 10% of people can develop scoposis, which may need to be corrected surgically or with braces.

Conclusion

Both sexes are equally plagued with Angelman syndrome. In the general population, Angelman syndrome is thought to affect 1 in 12,000 to 20,000 inspaniduals. It is challenging to estimate the disorder s prevalence in the general community since many cases may go undetected. Currently, no genetic therapy or curative medication is available to treat Angelman syndrome. However, advances in neuroscience and gene therapy techniques have great potential.